| Dr Yvette Renee Kaunismaki, MD | |
|
480 Galletti Way, Sparks, NV 89431-5564 | |
| (775) 688-2001 | |
| (775) 688-2004 |
| Full Name | Dr Yvette Renee Kaunismaki |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 480 Galletti Way, Sparks, Nevada |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750595252 | NPI | - | NPPES |
| 13378 | Other | NV | STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 13378 (Nevada) | Primary |
| Entity Name | State Of Nevada |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760572010 PECOS PAC ID: 9234022153 Enrollment ID: O20040212000160 |
News Archive
Any scientist who studies groups of people knows that the characteristics of the "sample" - the group of people selected for the study - can profoundly impact the study's findings. To produce the most accurate findings, a study group ought to be as similar as possible to the people in the larger population you want to say something about.
Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.
At the 64th ASMS Conference, Bruker introduces an entirely new mass spectrometry technology platform: the innovative timsTOF™ system combines very high ion mobility resolution greater than 200, using Bruker's proprietary Trapped Ion Mobility Spectrometry (TIMS), with Bruker's ultra-high performance ESI-QTOF mass spectrometry.
A fully automated immunochemistry assay is highly sensitive and specific for detecting anaplastic lymphoma kinase fusion in primary lung adenocarcinomas, Chinese researchers report.
Soligenix, Inc., a late-stage biopharmaceutical company, announced today that it has entered into common stock purchase agreements with both existing and new investors totaling approximately $5.16 million. Soligenix's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.
› Verified 2 days ago
| Entity Name | Yvette Kaunismaki Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184029464 PECOS PAC ID: 1355627597 Enrollment ID: O20170424001698 |
News Archive
Any scientist who studies groups of people knows that the characteristics of the "sample" - the group of people selected for the study - can profoundly impact the study's findings. To produce the most accurate findings, a study group ought to be as similar as possible to the people in the larger population you want to say something about.
Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.
At the 64th ASMS Conference, Bruker introduces an entirely new mass spectrometry technology platform: the innovative timsTOF™ system combines very high ion mobility resolution greater than 200, using Bruker's proprietary Trapped Ion Mobility Spectrometry (TIMS), with Bruker's ultra-high performance ESI-QTOF mass spectrometry.
A fully automated immunochemistry assay is highly sensitive and specific for detecting anaplastic lymphoma kinase fusion in primary lung adenocarcinomas, Chinese researchers report.
Soligenix, Inc., a late-stage biopharmaceutical company, announced today that it has entered into common stock purchase agreements with both existing and new investors totaling approximately $5.16 million. Soligenix's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Yvette Renee Kaunismaki, MD 480 Galletti Way, Sparks, NV 89431-5564 Ph: (775) 688-2001 | Dr Yvette Renee Kaunismaki, MD 480 Galletti Way, Sparks, NV 89431-5564 Ph: (775) 688-2001 |
News Archive
Any scientist who studies groups of people knows that the characteristics of the "sample" - the group of people selected for the study - can profoundly impact the study's findings. To produce the most accurate findings, a study group ought to be as similar as possible to the people in the larger population you want to say something about.
Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.
At the 64th ASMS Conference, Bruker introduces an entirely new mass spectrometry technology platform: the innovative timsTOF™ system combines very high ion mobility resolution greater than 200, using Bruker's proprietary Trapped Ion Mobility Spectrometry (TIMS), with Bruker's ultra-high performance ESI-QTOF mass spectrometry.
A fully automated immunochemistry assay is highly sensitive and specific for detecting anaplastic lymphoma kinase fusion in primary lung adenocarcinomas, Chinese researchers report.
Soligenix, Inc., a late-stage biopharmaceutical company, announced today that it has entered into common stock purchase agreements with both existing and new investors totaling approximately $5.16 million. Soligenix's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.
› Verified 2 days ago
Dr. Christopher Charles, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 480 Galletti Way, Sparks, NV 89431 Phone: 775-688-2001 Fax: 775-688-2192 | |
Yixiang Chen, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 480 Galletti Way, Sparks, NV 89431 Phone: 775-688-2001 Fax: 775-688-2192 | |
Usha Kiran Nuthi, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2385 E Prater Way, Suite 205, Sparks, NV 89434 Phone: 775-356-4888 Fax: 775-356-4890 | |
Vasudha Ahuja, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 480 Galletti Way, Sparks, NV 89431 Phone: 775-688-2001 Fax: 775-688-2192 | |
Ira Pauly, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 480 Galletti Way, Sparks, NV 89431 Phone: 775-688-2001 Fax: 775-688-2192 | |
Dr. Howard Hale Henson, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 500 Galletti Way, Sparks, NV 89431 Phone: 775-688-1900 Fax: 775-688-1962 |